During 5 years from January 1995 to December 1999, in the Department of Urology of B×nh D©n hospital, we have treated 193 cases of urogenital tuberculosis coming from South Vietnam in which there were 86 cases (44.55%) with complication of ureteral stenosis in many different forms and degrees. The most common stenotic lesions were pelvic and juxtavesical stenosis (61.62%), the mid-ureteral stenosis and uretero - pelvic stenosis were rare (8.13% and 1.16%, respectively), or segmental stenosis (20.93%). In 86 cases of ureteral stenosis, there were 13 cases (15.115) with concomitant deterioration of the ipsilateral kidney. Treatment for this specific complication of the disease usually faces many difficulties, because of many internal and external causes.
Urethral Diseases ; Tuberculosis, Urogenital ; therapeutics

Background: Most abdominal surgery can be done by laparoscopic method. For urologic surgery, laparoscopic surgery is used to cut the kidney, prostate, seminal vesicles and get urinary stones, including the ureter stones.\r\n', u'Objectives: Contribute to improving treatment effects ureter stones by lapasoscopy tranperitoneal ureterolithotomy\r\n', u'Subjects and method: Laparoscopic transperitoneal ureterolithotomy was attempted in 90 patients (50 men and 34 women) with an age range of 22 \ufffd?75 years (mean 43.60+ 11.97 years). Learn characteristics of ureteral calculi (X-ray, ultrasound, urinary map vein) and surgical methods.\r\n', u'Results:The results showed that: Most ureterolith at L3 vertebral level (55.6%) and L4 (40.0%). The stone size ranged from 8 to 22mm (mean 13.87+ 3.25mm) and an average width 4 to 12mm (mean 6.96 + 1.82mm). Most cases of ureteral calculi with the situation fluid in the kidney level 2 (76.7%). The stone has impacted in the upper and mid ureter. Two 10-mm and one 5mm trocars were used. Most cases of stage 2 nasal. The mean operative time was 57.22 + 15.51 minutes (30-90 minutes). \r\n', u'Conclusion: The authors conclude that laparoscopic ureterolithotomy by the transperitoneal approach is a safe and reliable minimally invasive procedure. For large, hard, long-standing and impacted ureteric calculi, one laparoscopicureterolithotomy is an initial therapy\r\n', u'
Ureterostomy ; Laparoscopy

Background: Little is known about the burden of hair loss following coronavirus disease 2019 (COVID-19) infection in older adults. This study investigated the prevalence and associated factors of hair loss in older outpatients in Vietnam. Materials and methods: Between March 2022 and July 2022, this multicenter cross-sectional study included 547 older patients (aged ≥ 60 years; mean age 68.5 ± 6.9 years; men 27.1%) from three post-COVID-19 clinics. Factors associated with hair loss were assessed using logistic regression. Results: In total, 63 patients (11.5%) experienced hair loss. All of the patients with hair loss exhibited diffuse type. In the adjusted model, factors associated with hair loss were women (odds ratio [OR], 3.36; 95% confidence interval [CI], 1.43 - 7.89; P = 0.005), single or divorced in marital status (OR, 3.27; 95% CI, 1.33 - 8.02; P = 0.01), and history of COVID-19 related hospitalization (OR, 5.17; 95% CI, 2.44 - 10.95; P < 0.001). Conclusion: Our study found a substantial prevalence of post-COVID-19 hair loss in older outpatients.

The low-density lipoprotein cholesterol (LDL-C) is established as a causative agent of atherosclerotic cardiovascular disease (ASCVD) and lowering plasma LDL-C levels represents the main approach to reduce the risk of cardiovascular events. Statins remain the cornerstone of drug therapy for dyslipidemia. Although moderate- to high- intensity statin therapy has demonstrated consistent benefits for secondary prevention of cardiovascular events, statin monotherapy is insufficient to achieve the guideline-recommended LDL-C levels for high- and very high-risk patients. Some patients cannot tolerate statins, especially when taking long-term high doses. Several non-statin drugs that have a complementary mechanism of action to statins are now available, including ezetimibe, monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9 mAb), and, more recently, inclisiran, bempedoic acid, and evinacumab. Considering the recommendations from guidelines by domestic and international cardiovascular associations, combining these drugs should be contemplated to attain treatment goals for patients.